Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call a...(Othertherapeutic development programs ar...)

Date:1/29/2008

Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release contains forward-looking statements regarding Sangamo's current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include the early stage of ZFP Therapeutic development, uncertainties related to the timing of initiation and completion of clinical trials, and whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo will be able to develop commercially viable gene based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the company's operations and business environments. These risks and uncertainties are described more fully in the company's' Annual Reports on Form 1
'/>"/>

SOURCE Sangamo BioSciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing
2. Sangamo BioSciences to Present at the BMO Capital Markets Health Care Conference
3. Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
4. Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
5. Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast
6. Sangamo BioSciences to Present at the 2007 BIO InvestorForum
7. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
8. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
9. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
10. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
11. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models